Label Changes for:
Ditropan XL (oxybutynin chloride, USP) Extended Release tablets
Changes have been made to the ADVERSE REACTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- July 2009
- memory impairment
- Cardiac Disorders: QT interval prolongation